"NE3107 Shows Promise for Improving Health"

BioVie's drug NE3107 shows potential improvements in motor and non-motor symptoms for Parkinson’s Disease patients and may realign physiological processes for Alzheimer’s patients, as indicated by data to be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024. The Phase 2a trial in Parkinson’s Disease suggests significant improvements in non-motor symptoms and motor control for NE3107-treated patients, while the Phase 3 trial in mild to moderate Alzheimer’s Disease indicates potential physiological realignment and improvements in cognitive and functional measures. These findings support further clinical investigation of NE3107 in late-phase trials for both conditions.